Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-09-12

AUTHORS

Masamitsu Yanada

ABSTRACT

Allogeneic hematopoietic cell transplantation (HCT) is the most potent therapy for preventing relapse of acute myeloid leukemia (AML). Although its efficacy is compromised by a high risk of treatment-related morbidity and mortality, an accumulating body of evidence has led to the general recommendation favoring allogeneic HCT from a matched sibling donor during first complete remission (CR1) for younger patients with cytogenetically intermediate- or high-risk AML. Over the past few decades, this field has seen a great many advancements. The indications for allogeneic HCT have been refined by taking into account the molecular profiles of leukemic cells and the degree of comorbidities. The introduction of high-resolution human leukocyte antigen-typing technology and advances in immunosuppressive therapy and supportive care measures have improved outcomes in alternative donor transplantation, while the parallel growth of unrelated donor registries and greater use of umbilical cord blood and haploidentical donors have considerably improved the chance of finding an alternative donor. The development of reduced-intensity and non-myeloablative conditioning has made it possible to receive allogeneic HCT for patients who might once have been considered ineligible due to advanced age or comorbidities. Thanks to these advances, the role of allogeneic HCT during CR1 has become progressively more important in the treatment of AML. More... »

PAGES

243-254

References to SciGraph publications

  • 2011-03-28. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS in BONE MARROW TRANSPLANTATION
  • 2011-08-29. Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS in BONE MARROW TRANSPLANTATION
  • 2014-02-03. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients in LEUKEMIA
  • 2012-07-13. Acute myeloid leukemia in older adults in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2012-09-03. Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation in BONE MARROW TRANSPLANTATION
  • 2005-09-29. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) in LEUKEMIA
  • 2004-01-12. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients in BONE MARROW TRANSPLANTATION
  • 2005-04-21. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison in LEUKEMIA
  • 2012-12-03. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT in BONE MARROW TRANSPLANTATION
  • 2009-01-08. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission in LEUKEMIA
  • 2012-01-13. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association in LEUKEMIA
  • 2010-01-09. Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2013-11-18. A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality in BONE MARROW TRANSPLANTATION
  • 2010-05-20. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission in LEUKEMIA
  • 2002-08-30. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy in LEUKEMIA
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s12185-014-1657-0

    DOI

    http://dx.doi.org/10.1007/s12185-014-1657-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1031936200

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/25212675


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hematopoietic Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myeloid, Acute", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Remission Induction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tissue Donors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation Conditioning", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transplantation, Homologous", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Hematology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, 470-1192, Toyoake, Japan", 
              "id": "http://www.grid.ac/institutes/grid.256115.4", 
              "name": [
                "Department of Hematology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, 470-1192, Toyoake, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yanada", 
            "givenName": "Masamitsu", 
            "id": "sg:person.01024604275.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024604275.66"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/leu.2010.102", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020924356", 
              "https://doi.org/10.1038/leu.2010.102"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2011.382", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027185181", 
              "https://doi.org/10.1038/leu.2011.382"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2011.69", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052594326", 
              "https://doi.org/10.1038/bmt.2011.69"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2403967", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023301181", 
              "https://doi.org/10.1038/sj.leu.2403967"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2013.178", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038814906", 
              "https://doi.org/10.1038/bmt.2013.178"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2014.55", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041831184", 
              "https://doi.org/10.1038/leu.2014.55"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2403770", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020634553", 
              "https://doi.org/10.1038/sj.leu.2403770"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-009-0483-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029319003", 
              "https://doi.org/10.1007/s12185-009-0483-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2012.236", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005426871", 
              "https://doi.org/10.1038/bmt.2012.236"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bmt.1704391", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036439121", 
              "https://doi.org/10.1038/sj.bmt.1704391"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2008.352", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024791794", 
              "https://doi.org/10.1038/leu.2008.352"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2402622", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033203364", 
              "https://doi.org/10.1038/sj.leu.2402622"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12185-012-1137-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034073951", 
              "https://doi.org/10.1007/s12185-012-1137-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2012.159", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048163896", 
              "https://doi.org/10.1038/bmt.2012.159"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2011.167", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044929323", 
              "https://doi.org/10.1038/bmt.2011.167"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-09-12", 
        "datePublishedReg": "2014-09-12", 
        "description": "Allogeneic hematopoietic cell transplantation (HCT) is the most potent therapy for preventing relapse of acute myeloid leukemia (AML). Although its efficacy is compromised by a high risk of treatment-related morbidity and mortality, an accumulating body of evidence has led to the general recommendation favoring allogeneic HCT from a matched sibling donor during first complete remission (CR1) for younger patients with cytogenetically intermediate- or high-risk AML. Over the past few decades, this field has seen a great many advancements. The indications for allogeneic HCT have been refined by taking into account the molecular profiles of leukemic cells and the degree of comorbidities. The introduction of high-resolution human leukocyte antigen-typing technology and advances in immunosuppressive therapy and supportive care measures have improved outcomes in alternative donor transplantation, while the parallel growth of unrelated donor registries and greater use of umbilical cord blood and haploidentical donors have considerably improved the chance of finding an alternative donor. The development of reduced-intensity and non-myeloablative conditioning has made it possible to receive allogeneic HCT for patients who might once have been considered ineligible due to advanced age or comorbidities. Thanks to these advances, the role of allogeneic HCT during CR1 has become progressively more important in the treatment of AML.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s12185-014-1657-0", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1076985", 
            "issn": [
              "0925-5710", 
              "1865-3774"
            ], 
            "name": "International Journal of Hematology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "101"
          }
        ], 
        "keywords": [
          "allogeneic hematopoietic cell transplantation", 
          "hematopoietic cell transplantation", 
          "acute myeloid leukemia", 
          "first complete remission", 
          "complete remission", 
          "cell transplantation", 
          "myeloid leukemia", 
          "high-risk acute myeloid leukemia", 
          "treatment of AML", 
          "alternative donor transplantation", 
          "treatment-related morbidity", 
          "supportive care measures", 
          "non-myeloablative conditioning", 
          "degree of comorbidity", 
          "umbilical cord blood", 
          "unrelated donor registries", 
          "immunosuppressive therapy", 
          "haploidentical donors", 
          "younger patients", 
          "donor transplantation", 
          "potent therapy", 
          "body of evidence", 
          "care measures", 
          "cord blood", 
          "advanced age", 
          "alternative donors", 
          "high risk", 
          "leukemic cells", 
          "clinical perspective", 
          "transplantation", 
          "donor registry", 
          "molecular profile", 
          "remission", 
          "comorbidities", 
          "patients", 
          "therapy", 
          "leukemia", 
          "general recommendations", 
          "donors", 
          "morbidity", 
          "relapse", 
          "registry", 
          "mortality", 
          "blood", 
          "greater use", 
          "efficacy", 
          "outcomes", 
          "age", 
          "CR1", 
          "treatment", 
          "risk", 
          "indications", 
          "cells", 
          "advances", 
          "evidence", 
          "recommendations", 
          "role", 
          "chance", 
          "measures", 
          "conditioning", 
          "body", 
          "profile", 
          "use", 
          "development", 
          "parallel growth", 
          "degree", 
          "decades", 
          "advancement", 
          "growth", 
          "introduction", 
          "perspective", 
          "account", 
          "technology", 
          "field", 
          "thanks"
        ], 
        "name": "Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective", 
        "pagination": "243-254", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1031936200"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s12185-014-1657-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "25212675"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s12185-014-1657-0", 
          "https://app.dimensions.ai/details/publication/pub.1031936200"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-10-01T06:39", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_639.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s12185-014-1657-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-014-1657-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-014-1657-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-014-1657-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-014-1657-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    228 TRIPLES      21 PREDICATES      123 URIs      100 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s12185-014-1657-0 schema:about N2886cad3f6fd44ccba95de9d915f1d1a
    2 N50d0e1026a1444efa903f769dac291ab
    3 N5ae3b996228a418686d34d318b44d390
    4 N651d986dec5b4262810a214f8e682651
    5 N699111553cdc4df4b790bcd70459267f
    6 N7355dea403154406a9371c9670cf3b6e
    7 N91daf933e3cd4d4c87a24f4f695bed09
    8 N9b7c92ce9f7149e793a6fb921158c29e
    9 anzsrc-for:11
    10 anzsrc-for:1102
    11 schema:author Ndab77966a39146768988e8ca471efed9
    12 schema:citation sg:pub.10.1007/s12185-009-0483-2
    13 sg:pub.10.1007/s12185-012-1137-3
    14 sg:pub.10.1038/bmt.2011.167
    15 sg:pub.10.1038/bmt.2011.69
    16 sg:pub.10.1038/bmt.2012.159
    17 sg:pub.10.1038/bmt.2012.236
    18 sg:pub.10.1038/bmt.2013.178
    19 sg:pub.10.1038/leu.2008.352
    20 sg:pub.10.1038/leu.2010.102
    21 sg:pub.10.1038/leu.2011.382
    22 sg:pub.10.1038/leu.2014.55
    23 sg:pub.10.1038/sj.bmt.1704391
    24 sg:pub.10.1038/sj.leu.2402622
    25 sg:pub.10.1038/sj.leu.2403770
    26 sg:pub.10.1038/sj.leu.2403967
    27 schema:datePublished 2014-09-12
    28 schema:datePublishedReg 2014-09-12
    29 schema:description Allogeneic hematopoietic cell transplantation (HCT) is the most potent therapy for preventing relapse of acute myeloid leukemia (AML). Although its efficacy is compromised by a high risk of treatment-related morbidity and mortality, an accumulating body of evidence has led to the general recommendation favoring allogeneic HCT from a matched sibling donor during first complete remission (CR1) for younger patients with cytogenetically intermediate- or high-risk AML. Over the past few decades, this field has seen a great many advancements. The indications for allogeneic HCT have been refined by taking into account the molecular profiles of leukemic cells and the degree of comorbidities. The introduction of high-resolution human leukocyte antigen-typing technology and advances in immunosuppressive therapy and supportive care measures have improved outcomes in alternative donor transplantation, while the parallel growth of unrelated donor registries and greater use of umbilical cord blood and haploidentical donors have considerably improved the chance of finding an alternative donor. The development of reduced-intensity and non-myeloablative conditioning has made it possible to receive allogeneic HCT for patients who might once have been considered ineligible due to advanced age or comorbidities. Thanks to these advances, the role of allogeneic HCT during CR1 has become progressively more important in the treatment of AML.
    30 schema:genre article
    31 schema:isAccessibleForFree true
    32 schema:isPartOf N0d5976f1e0d341b893847023fcf72ef7
    33 Nf50cd3ce2ddd4be0acd55cecbc08365b
    34 sg:journal.1076985
    35 schema:keywords CR1
    36 account
    37 acute myeloid leukemia
    38 advanced age
    39 advancement
    40 advances
    41 age
    42 allogeneic hematopoietic cell transplantation
    43 alternative donor transplantation
    44 alternative donors
    45 blood
    46 body
    47 body of evidence
    48 care measures
    49 cell transplantation
    50 cells
    51 chance
    52 clinical perspective
    53 comorbidities
    54 complete remission
    55 conditioning
    56 cord blood
    57 decades
    58 degree
    59 degree of comorbidity
    60 development
    61 donor registry
    62 donor transplantation
    63 donors
    64 efficacy
    65 evidence
    66 field
    67 first complete remission
    68 general recommendations
    69 greater use
    70 growth
    71 haploidentical donors
    72 hematopoietic cell transplantation
    73 high risk
    74 high-risk acute myeloid leukemia
    75 immunosuppressive therapy
    76 indications
    77 introduction
    78 leukemia
    79 leukemic cells
    80 measures
    81 molecular profile
    82 morbidity
    83 mortality
    84 myeloid leukemia
    85 non-myeloablative conditioning
    86 outcomes
    87 parallel growth
    88 patients
    89 perspective
    90 potent therapy
    91 profile
    92 recommendations
    93 registry
    94 relapse
    95 remission
    96 risk
    97 role
    98 supportive care measures
    99 technology
    100 thanks
    101 therapy
    102 transplantation
    103 treatment
    104 treatment of AML
    105 treatment-related morbidity
    106 umbilical cord blood
    107 unrelated donor registries
    108 use
    109 younger patients
    110 schema:name Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective
    111 schema:pagination 243-254
    112 schema:productId N2e4324f3c3cc4fdd828fdd45101e6dc6
    113 Na34711ec9b584dd6ad47065ece93bee5
    114 Nc1554d838cd4445ebeb3a10f9b68d913
    115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031936200
    116 https://doi.org/10.1007/s12185-014-1657-0
    117 schema:sdDatePublished 2022-10-01T06:39
    118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    119 schema:sdPublisher N5f468ce7487e45659d11ba39c6140945
    120 schema:url https://doi.org/10.1007/s12185-014-1657-0
    121 sgo:license sg:explorer/license/
    122 sgo:sdDataset articles
    123 rdf:type schema:ScholarlyArticle
    124 N0d5976f1e0d341b893847023fcf72ef7 schema:issueNumber 3
    125 rdf:type schema:PublicationIssue
    126 N2886cad3f6fd44ccba95de9d915f1d1a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Tissue Donors
    128 rdf:type schema:DefinedTerm
    129 N2e4324f3c3cc4fdd828fdd45101e6dc6 schema:name dimensions_id
    130 schema:value pub.1031936200
    131 rdf:type schema:PropertyValue
    132 N50d0e1026a1444efa903f769dac291ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Transplantation, Homologous
    134 rdf:type schema:DefinedTerm
    135 N5ae3b996228a418686d34d318b44d390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Transplantation Conditioning
    137 rdf:type schema:DefinedTerm
    138 N5f468ce7487e45659d11ba39c6140945 schema:name Springer Nature - SN SciGraph project
    139 rdf:type schema:Organization
    140 N651d986dec5b4262810a214f8e682651 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Remission Induction
    142 rdf:type schema:DefinedTerm
    143 N699111553cdc4df4b790bcd70459267f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Humans
    145 rdf:type schema:DefinedTerm
    146 N7355dea403154406a9371c9670cf3b6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Leukemia, Myeloid, Acute
    148 rdf:type schema:DefinedTerm
    149 N91daf933e3cd4d4c87a24f4f695bed09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Animals
    151 rdf:type schema:DefinedTerm
    152 N9b7c92ce9f7149e793a6fb921158c29e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Hematopoietic Stem Cell Transplantation
    154 rdf:type schema:DefinedTerm
    155 Na34711ec9b584dd6ad47065ece93bee5 schema:name doi
    156 schema:value 10.1007/s12185-014-1657-0
    157 rdf:type schema:PropertyValue
    158 Nc1554d838cd4445ebeb3a10f9b68d913 schema:name pubmed_id
    159 schema:value 25212675
    160 rdf:type schema:PropertyValue
    161 Ndab77966a39146768988e8ca471efed9 rdf:first sg:person.01024604275.66
    162 rdf:rest rdf:nil
    163 Nf50cd3ce2ddd4be0acd55cecbc08365b schema:volumeNumber 101
    164 rdf:type schema:PublicationVolume
    165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    166 schema:name Medical and Health Sciences
    167 rdf:type schema:DefinedTerm
    168 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    169 schema:name Cardiorespiratory Medicine and Haematology
    170 rdf:type schema:DefinedTerm
    171 sg:journal.1076985 schema:issn 0925-5710
    172 1865-3774
    173 schema:name International Journal of Hematology
    174 schema:publisher Springer Nature
    175 rdf:type schema:Periodical
    176 sg:person.01024604275.66 schema:affiliation grid-institutes:grid.256115.4
    177 schema:familyName Yanada
    178 schema:givenName Masamitsu
    179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024604275.66
    180 rdf:type schema:Person
    181 sg:pub.10.1007/s12185-009-0483-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029319003
    182 https://doi.org/10.1007/s12185-009-0483-2
    183 rdf:type schema:CreativeWork
    184 sg:pub.10.1007/s12185-012-1137-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034073951
    185 https://doi.org/10.1007/s12185-012-1137-3
    186 rdf:type schema:CreativeWork
    187 sg:pub.10.1038/bmt.2011.167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044929323
    188 https://doi.org/10.1038/bmt.2011.167
    189 rdf:type schema:CreativeWork
    190 sg:pub.10.1038/bmt.2011.69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052594326
    191 https://doi.org/10.1038/bmt.2011.69
    192 rdf:type schema:CreativeWork
    193 sg:pub.10.1038/bmt.2012.159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048163896
    194 https://doi.org/10.1038/bmt.2012.159
    195 rdf:type schema:CreativeWork
    196 sg:pub.10.1038/bmt.2012.236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005426871
    197 https://doi.org/10.1038/bmt.2012.236
    198 rdf:type schema:CreativeWork
    199 sg:pub.10.1038/bmt.2013.178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038814906
    200 https://doi.org/10.1038/bmt.2013.178
    201 rdf:type schema:CreativeWork
    202 sg:pub.10.1038/leu.2008.352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024791794
    203 https://doi.org/10.1038/leu.2008.352
    204 rdf:type schema:CreativeWork
    205 sg:pub.10.1038/leu.2010.102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020924356
    206 https://doi.org/10.1038/leu.2010.102
    207 rdf:type schema:CreativeWork
    208 sg:pub.10.1038/leu.2011.382 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027185181
    209 https://doi.org/10.1038/leu.2011.382
    210 rdf:type schema:CreativeWork
    211 sg:pub.10.1038/leu.2014.55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041831184
    212 https://doi.org/10.1038/leu.2014.55
    213 rdf:type schema:CreativeWork
    214 sg:pub.10.1038/sj.bmt.1704391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036439121
    215 https://doi.org/10.1038/sj.bmt.1704391
    216 rdf:type schema:CreativeWork
    217 sg:pub.10.1038/sj.leu.2402622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033203364
    218 https://doi.org/10.1038/sj.leu.2402622
    219 rdf:type schema:CreativeWork
    220 sg:pub.10.1038/sj.leu.2403770 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020634553
    221 https://doi.org/10.1038/sj.leu.2403770
    222 rdf:type schema:CreativeWork
    223 sg:pub.10.1038/sj.leu.2403967 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023301181
    224 https://doi.org/10.1038/sj.leu.2403967
    225 rdf:type schema:CreativeWork
    226 grid-institutes:grid.256115.4 schema:alternateName Department of Hematology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, 470-1192, Toyoake, Japan
    227 schema:name Department of Hematology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, 470-1192, Toyoake, Japan
    228 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...